with a number of candidate compounds dropped from development due to pharmacokinetic difficulties in clinical studies. Pharmaceutical companies have therefore attempted to predict human pharmacokinetic profiles of candidate compounds through semiquantitative screening approaches, selecting only those compounds with appropriate pharmacokinetic profiles for subsequent focus. Consequently, these factors of attrition have been dramatically reduced in drug development. With improvement in pharmacokinetic profiles achieved, poor efficacy and safety now represent the major causes of attrition in clinical studies. The situation has remained thus far, and the purpose of predicting human pharmacokinetics has changed from screening by semi-quantitative prediction to quantitative prediction. In addition, the target of prediction has changed from compounds metabolized by cytochrome P450 (P450) enzymes to those metabolized by non-P450 enzymes and the substrates of transporters. Here, I discuss future perspectives for predicting human pharmacokinetics.
Accurate prediction of hepatic clearance is very important in the prediction of human pharmacokinetics. To this end, the utility of in vitro-in vivo extrapolation using human biological samples, such as human hepatic microsomes, has been examined in the prediction of hepatic clearance. This in vitro-in vivo extrapolation largely involves compounds metabolized by P450, which is the most important enzyme in drug metabolism.
2) However, few studies have attempted prediction of hepatic clearance for non-P450 enzymes, such as UDP-glucuronosyltransferase, carbonyl/ aldo-keto reductase, aldehyde oxidase, flavin-containing monooxygenase or monoamine oxidase.
3)
Recently, drug transporters have received considerable attention as factors that affect pharmacokinetic profiles. 4) Evaluation of methods for prediction of pharmacokinetic profiles in humans for compounds that are the substrates of transporters is also important. In addition, research into the prediction of extrahepatic clearance, such as intestinal clearance, has been limited. 5) Future studies should focus on the prediction of human pharmacokinetics for non-P450 enzymes, transporters and extrahepatic organs.
At present, poor efficacy and safety are considered the major causes of attrition in drug development, as mentioned above. As such, research may soon focus on predicting the time course of blood drug concentration, as the pharmacokinetic behavior of a drug is a critical determinant of both its efficacy and safety.
6,7) For predicting the time course of blood drug concentration in humans, PBPK models have been used as conventional methods with new useful approaches being recently proposed. [8] [9] [10] Prediction of the drug distribution to the pharmacological and toxicological target organs is also required. Recently, personalized medicine has attracted attention in the pharmaceutical field. This would enable the prediction of pharmacokinetics for an individual and differences between healthy subjects and patients, males and females, and adults and children.
To solve these issues of pharmacokinetic prediction, the introduction of the following tools should be considered:
: More reliable in silico approaches and PBPK models, and the introduction of systems biology for more accurate prediction : Genetically modified or transgenic mouse models developed for drug metabolizing enzymes and transporters, and chimeric mice with humanized livers : Bio-imaging technologies (e.g. PET and imaging mass spectrometry) for predicting distribution : iPS cell-derived human hepatocytes for predicting pharmacokinetics related to personalized medicine : In vitro experimental systems which accurately reflect in vivo situations (e.g. optimization of hepatocyte cultivation systems and bioreactor systems) Research into the prediction of human pharmacokinetics has been conducted mainly for low-molecular-weight compounds. Pharmaceutical companies have begun to focus on new fields such as cell-based medicine, therapeutic biologics including monoclonal antibodies and nucleic acid medicine. However, the contribution of drug metabolism and pharmacokinetic scientists is limited in these new fields compared to that for low-molecular-weight drugs. In the future, drug metabolism and pharmacokinetics researchers should expand their fields of study to increase their knowledge and gain access to new evaluation technologies, familiarizing themselves with new prediction methods and mechanisms of drug metabolism and pharmacokinetics not encountered in studies of low-molecularweight compounds.
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